AGC Biologics announced the completion of a new manufacturing building at its Copenhagen, Denmark, campus in early June 2024. The expansion doubles the site’s single-use bioreactor capacity for mammalian-based services to produce an additional 150 batches of drug product per year. The completed project adds 19,000 m2 of space, including a large manufacturing floor, expanded quality control and process development lab space, utilities, and a fully dedicated warehouse. Source: Biopharm International 11/6/2024